| Literature DB >> 35055121 |
Olubodun Michael Lateef1, Michael Olawale Akintubosun1, Olamide Tosin Olaoba2, Sunday Ocholi Samson1, Malgorzata Adamczyk1.
Abstract
The evolutional development of the RNA translation process that leads to protein synthesis based on naturally occurring amino acids has its continuation via synthetic biology, the so-called rational bioengineering. Genetic code expansion (GCE) explores beyond the natural translational processes to further enhance the structural properties and augment the functionality of a wide range of proteins. Prokaryotic and eukaryotic ribosomal machinery have been proven to accept engineered tRNAs from orthogonal organisms to efficiently incorporate noncanonical amino acids (ncAAs) with rationally designed side chains. These side chains can be reactive or functional groups, which can be extensively utilized in biochemical, biophysical, and cellular studies. Genetic code extension offers the contingency of introducing more than one ncAA into protein through frameshift suppression, multi-site-specific incorporation of ncAAs, thereby increasing the vast number of possible applications. However, different mediating factors reduce the yield and efficiency of ncAA incorporation into synthetic proteins. In this review, we comment on the recent advancements in genetic code expansion to signify the relevance of systems biology in improving ncAA incorporation efficiency. We discuss the emerging impact of tRNA modifications and metabolism in protein design. We also provide examples of the latest successful accomplishments in synthetic protein therapeutics and show how codon expansion has been employed in various scientific and biotechnological applications.Entities:
Keywords: amber suppressors; frameshift suppressors; genetic code; metabolism; orthogonality; synthetic biology; tRNA modifications
Mesh:
Substances:
Year: 2022 PMID: 35055121 PMCID: PMC8779196 DOI: 10.3390/ijms23020938
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic illustration of the general principles for the site-specific incorporation of ncAA into proteins in vivo. The natural translational system involves the activity of endogenous synthetase, which charges the endogenous tRNA with natural amino acids (NAAs), which is presented as a red oval shape. The orthogonal translational system is applied to site-specifically incorporate ncAA into proteins. Orthogonal aminoacyl-tRNA synthetase acylates the orthogonal tRNA with a noncanonical amino acid. The acylated orthogonal tRNA introduces the ncAA at a specific site complementary to the unique codon, thereby incorporating it into the ORF that encodes the protein of interest (ncAA is represented by the red star).
Figure 2(A) Schematic illustration of the different approaches that are used for the incorporation of ncAA. (A) Amber codon suppression. (B) Rare sense codon reassignment. (C) Triplet codon and anticodon composed of natural and synthetic bases. (D) Frameshift suppression with the use of extended codon (e.g., a quadruplet codon).
Orthogonal tRNAs derived from different species discussed in the review and their hosts of expression.
| Host of Orthogonal tRNA | tRNA | Anticodons | Noncanonical Amino Acids | Host Organism | Refs |
|---|---|---|---|---|---|
| Archaeal | |||||
|
| tRNATyr | CUA |
| [ | |
| tRNACys | CUA |
| [ | ||
| tRNAPyl | UCCU | N-3-(tert-butyloxycarbonyl)-L-lysine (Boc-Lys) | [ | ||
| tRNASer2 | UCCU | p-azido-L-phenylalanine |
| [ | |
|
| tRNAPyl | CUA |
| [ | |
|
| [ | ||||
|
| tRNAPyl | CGGA, CGGG | [ | ||
|
| tRNAPyl | CUA |
| [ | |
|
| [ | ||||
|
| [ | ||||
| Mammalian cells | [ | ||||
|
| [ | ||||
| [ | |||||
| UCA |
| [ | |||
|
| |||||
|
| tRNATyr | CCCG | 2-naphthylalanine L-lysine |
| [ |
| tRNAPhe | CUA |
| [ | ||
| CUA |
| [ | |||
| ACCU, ACCG | [ | ||||
| AGGG, AGAG | |||||
| AUAG, ACCC | |||||
| AGAG, CGGU | |||||
| CGCU, CCCU | |||||
| CUAU, GGGU | |||||
|
| |||||
|
| tRNATyr | CUA | 3-iodo-L-tyrosine |
| [ |
| Mammalian cells | [ | ||||
|
| [ | ||||
| 3-iodo-L-tyrosine | Mammalian cells | [ | |||
|
| |||||
| 4-azido-l-phenylalanine | |||||
| o-methyl-L-tyrosine | |||||
| tRNALeu | CUA |
| [ | ||
| o-methyltyrosine |
| ||||
| α-amino-caprylic-acid | [ | ||||
| o-nitrobenzyl cysteine | |||||
|
| tRNATrp | UCA | 5-hydroxytryptophan | Mammalian cells | [ |
|
| tRNATyr | CUA | Mammalian cells | [ | |
| [ | |||||
tRNA modifications in the anticodon stem in Saccharomyces cerevisiae and Escherichia coli and the respective modifying enzymes to be manipulated for the improvement of ncAA incorporation efficiency.
| Anticodon Loop Position |
| Enzymes | Refs |
| Enzymes | Refs | Role during Incorporation |
|---|---|---|---|---|---|---|---|
| 26 | m22G | Trm1 | [ |
| - | - | Improves translation fidelity efficiency |
| 32 | Cm | Trm7 | [ | Cm, Um | TrmJ | [ | |
| m3C, | Trm140 | [ | s2C | IscS, TtcA | [ | ||
| Ψ | Pus8 | [ | Ψ | RluA | [ | ||
| 34 | Cm, Gm, cmnm5Um | Trm7/Trm7 | [ | Cm, Um | TrmL | [ | |
| ncm5U | Elp complex | [ | cmnm5Um | TrmL | [ | ||
| m5C | Trm4 | [ | ac4C | TmcA | [ | ||
| ψ | Pus1 | [ | mnm5se2U | TrmL | [ | ||
| mcm5s2U | Uba4 | [ | s2U | IscS | [ | ||
| A → I | Tad2,3 | [ | A → I | TadA | [ | ||
| 36 | Ψ | Pus1 | [ | i6A | MiaA | [ | |
| 37 | m1G | Trm5 | [ | m1G | TrmD | [ | |
| m2A | RlmN | [ | |||||
| m1I | Trm5 | [ | m6A | TrmN6 | [ | ||
| i6A | MiaA | ||||||
| yW | Tyw1-4 | [ | ms2i6A | MiaB | |||
| m6t6A | TrmO | ||||||
| I6A | Mod5 | [ | |||||
| 38 | Ψ | Pus3 | [ | Ψ | TruA | [ | |
| 40 | m5C | Trm4 | [ | Ψ | TruA | [ |
Legend: Cm, 2′-O-methylcytidine; m1G, 1-methylguanosine; Gm, 2′-O-methylguanosine; m11, 1 methylinosine; ac4C, N4-acetylcytidine; ψ, pseudouridine; mcm5Um, 5-carbamoylmethyl-2′-O-methyluridine; i6A, N6-isopentenyladenosine; ms2i6A, 3-methylcytidine; 2-methyl-thio N6 isopentenyladenosine; yW, wybutosine, I, inosine; ac4C, N4-acetylcytidine; m3C, 3-methylcytidine; mcm5U, 5 carbamoylmethyluridine; mcm5Um, 5-carbamoylmethyl-2’-O-methyluridine; mcm5s2U, 5-methoxycarbonylmethyl-2-thiouridine; Um, 2’-O-methyluridine; m5C, 5-methylcytidine; mnm, 5-methylaminomethyl-2-selenouridine.
Figure 3The metabolic pathways that provide precursors necessary for the tRNA modifying enzymes in eukaryotes. The mitochondrion metabolic activity plays a vital role in tRNA modification. The single-carbon metabolism in the mitochondrion maintains the appropriate cytoplasmic pool of tetrahydrofolate (THF). The folate cycle cross-talks with the methionine cycle in a highly dependent manner, thereby providing SAM, a methyl donor for tRNA methyltransferase reaction. The mitochondria also supply an iron–sulfur (Fe/S) cluster that is transported via the Atm1 transporter into the cytosol. The cytoplasmic iron–sulfur protein assembly machinery produces the cytoplasmic iron–sulfur cluster that is essential for tRNA thiolation. In addition, intermediary metabolic pathways in the mitochondria usually produce acetyl-CoA, which serves as a donor of acetyl moiety for the tRNA isopentenylation pathway and most acetyl transferase reactions, including tRNA acetylation. The glycolytic pathway serves as a major source of energy for tRNA synthesis. Overall, the modification hotspots of tRNA are also shown, including their positions. (SAM: S-adenosylmethionine; 3-P. pyruvate: 3-phosphohydroxy pyruvate; ISC: iron–sulfur cluster; 5,10 MTHF: N,N-methylene tetrahydrofolate; FTHF: 10-formyltetrahydrofolate; SHMT: serine hydroxymethyltransferase; PRPP: phosphoribosyl pyrophosphate; DMAPP: dimethylallylpyrophosphate).
Figure 4Modifications of protein-based drugs to target tumor cells. (a) The application of protein or chemo drug in tumor therapy using ncAA-mediated chemical alteration to improve the pharmacokinetic properties of the drugs to targeted tumor cells. A protein modifier (orange thread) can be used for the controlled drug delivery of a protein drug (black woven thread), thereby enhancing the drug action against tumor cell. All red droplets represent ncAA with a highly reactive side chain. (b) Schematic representation of bioconjugate used for the selective delivery of a drug of interest to cancerous cells using a drug–ncAA–antibody complex. The protein drug is conjugated to the reactive side chain of the ncAA by a cross-linker.
Figure 5Applications of genetic code expansion.